Off-label use of tamoxifen in a Chinese tertiary care hospital
- 117 Downloads
Background Tamoxifen is an estrogen receptor modulator used for the treatment of breast cancer; however, currently, it is used in many off-label indications. Objective To investigate the prevalence of tamoxifen off-label prescribing and explore available scientific evidence that supports those uses in outpatients. Setting Xiamen maternity and child health care hospital in Xiamen city of China. Method All the prescriptions of outpatients receiving tamoxifen were exported from an electronic prescribing system during a 1-year period. Tamoxifen use was then classified as either on- or off-label according to the criteria we established previously, and the details of the off-label prescriptions were collected. Logistic regression was applied to explore predictive variables. Evidence search was limited to Up-To-Date, the Micromedex database and PubMed. Main outcome measure The rate of off-label use, risk factors identified by logistic regression and evidence exhibition. Results A total of 75% of all the prescriptions available were classified as off-label use. Hyperplasia of the breast was the most frequently prescribed off-label indication. According to the analysis of logistic regression, male patients, patients less than 34 years old, and physicians with a higher professional title were more likely associated with off-label prescribing. After a search in Up-To-Date, the Micromedex database and PubMed, only male infertility, atypical hyperplasia, mastodynia, peripheral precocious puberty and gynecomastia were found to have strong evidence supporting the use of tamoxifen off-label (22.75%). Conclusion Although the off-label use of tamoxifen was common in our hospital, there was a relative shortage of evidence available supporting those uses.
KeywordsChina Off-label use Tamoxifen
We would like to thank engineer Xu Jianbao (Information Services Department), for her assistance in extracting data from the Hospital Information System and pharmacist Liao Yufang for screening and managing the eligible data.
No external funding was obtained for this study.
Conflicts of interest
The authors declare that they have no conflict of interest.
- 6.Sawathiparnich P, Osuwanaratana P, Santiprabhob J, Likitmaskul S. Tamoxifen improved final height prediction in a girl with McCune–Albright syndrome: patient report and literature review. J Pediatr Endocr Met. 2006;19(1):81–6.Google Scholar
- 15.Wolters Kluwer. UpToDate [database on the Internet]. 2017. http://www.uptodatechina.com/. Accessed: 30 Sept 2017.
- 16.Truven Health Analytics. Micromedexsolutions [database on the Internet]. 2017. http://www.micromedexsolutions.com. Accessed: 30 Sept 2017.
- 17.Field MJ, Lohr KN, editors. Committee to advise the public health service on clinical practice guidelines, Institute of Medicine. Clinical Practice Guidelines: Directions for a New Program. Washington: National Academies Press (US); 1990.Google Scholar
- 18.National Center for Biotechnology Information. Pubmed [database on the Internet]. 2017. https://www.ncbi.nlm.nih.gov/pubmed. Accessed 30 Sept 2017.
- 19.Product Information: Tamoxifen oral tablets. Shanghai Forward Pharmaceutical Co, Ltd. 2015.Google Scholar
- 36.Visvanathan K, Chlebowski RT, Hurley P, Col NF, Ropka M, Collyar D, et al. American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol. 2009;27(19):3235–58.CrossRefGoogle Scholar
- 37.Levine M, Moutquin JM, Walton R, Feightner J. Chemoprevention of breast cancer. A joint guideline from the Canadian Task Force on Preventive Health Care and the Canadian Breast Cancer Initiative’s Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. CMAJ. 2001;164(12):1681–90.PubMedPubMedCentralGoogle Scholar